TY  -  JOUR
AU  -  Valsecchi, Paolo
AU  -  Barlati, Stefano
AU  -  Garozzo, Andrea
AU  -  Deste, Giacomo
AU  -  Nibbio, Gabriele
AU  -  Turrina, Cesare
AU  -  Sacchetti, Emilio
AU  -  Vita, Antonio
T1  -  Paliperidone palmitate in short- and long-term treatment 
of schizophrenia
PY  -  2019
Y1  -  2019-11-01
DO  -  10.1708/3281.32542
JO  -  Rivista di Psichiatria
JA  -  Riv Psichiatr
VL  -  54
IS  -  6
SP  -  235
EP  -  248
PB  -  Il Pensiero Scientifico Editore
SN  -  2038-2502
Y2  -  2026/05/14
UR  -  http://dx.doi.org/10.1708/3281.32542
N2  -  SUMMARY. Poor adherence to treatment remains a major problem in the management of patients with schizophrenia. In the 60s, first generation antipsychotics in depot formulation have been introduced on the market with the aim to improve adherence to therapy. However, the limited effectiveness on negative symptoms and the tendency to induce extrapyramidal side effects has limited their use. Currently there are five second-generation antipsychotic long-acting formulations and the use of these drugs has definitely changed perspective: they are no more restricted as compounds intended to improve compliance, but they can be considered first-line drugs with proven efficacy and good tolerability. In this narrative review the efficacy and tolerability of paliperidone palmitate, as well as the economic impact of the use of this particular molecule, have been evaluated in the short- and long-term treatment of schizophrenia. Taking into account the results of different studies, paliperidone, especially in his long-acting formulation, can be considered a viable and effective treatment for patients with schizophrenia, both in the short- and in the long term.
ER  -